Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

MIXED(19)
PROCEDURE(4)
DRUG(4)
Rituximab
3 trials
phase_1phase_1_2phase_2
university-of-washington
Pembrolizumab
2 trials
phase_1_2phase_2
university-of-washington
Copanlisib
2 trials
phase_1phase_2
university-of-washington
Doxorubicin Hydrochloride
1 trial
phase_1_2
university-of-washington
Etoposide
1 trial
phase_1_2
university-of-washington
FDG-Positron Emission Tomography
1 trial
phase_1_2
university-of-washington
Glofitamab
1 trial
phase_1_2
university-of-washington
Dexamethasone
1 trial
phase_1
university-of-washington

+15 more interventions

23 unique interventions3 categories

Analytics

Trial Phases

Phase 13
Phase 24

Trial Status

Completed1
Terminated3
Other1

Role Distribution

Principal Investigator5
PI Rate100%

Activity Timeline

Clinical Trials (5)

NCT04231877Phase 1/2Active Not Recruiting
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
Aggressive Non-Hodgkin LymphomaALK-Positive Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise Specified+6 more
PrincipalinvestigatorStart date: 2020-10-27
NCT04156828Phase 1Terminated
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma
Grade 3b Follicular LymphomaNon-Hodgkin's LymphomaRecurrent Diffuse Large B-Cell Lymphoma+2 more
PrincipalinvestigatorStart date: 2020-03-31
NCT04155840Phase 2Terminated
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic LeukemiaLymphoid LeukemiaNon-Hodgkin's Lymphoma+1 more
PrincipalinvestigatorStart date: 2020-01-31
NCT03776864Phase 2Terminated
Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Hodgkin's Lymphoma
PrincipalinvestigatorStart date: 2019-09-26
NCT03331341Phase 1/2Completed
Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma
Classical Hodgkin Lymphoma
PrincipalinvestigatorStart date: 2019-01-09

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Arnon Nagler, MD

Chaim Sheba Medical Center

Related
12 trials

Shared therapeutic areas:

Hodgkin DiseaseLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell+1 more
Similarity Score7%

Helen Heslop, MD

Baylor College of Medicine

Related
17 trials

Shared therapeutic areas:

Lymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-CellClassical Hodgkin Lymphoma+1 more
Similarity Score7%

Mary Horowitz, MD

Center for International Blood and Marrow Transplant Research

Related
24 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellHodgkin DiseaseLymphoma, Non-Hodgkin
Similarity Score5%

Mitchell Cairo, MD

New York Medical College

Related
14 trials

Shared therapeutic areas:

Lymphoma, Non-HodgkinHodgkin DiseaseClassical Hodgkin Lymphoma
Similarity Score5%

Yves Beguin, MD, PhD

CHU-ULg

Related
7 trials

Shared therapeutic areas:

Hodgkin DiseaseLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Non-Hodgkin
Similarity Score5%

Thomas E. Witzig, MD

Mayo Clinic

Related
12 trials

Shared therapeutic areas:

Aggressive Non-Hodgkin LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Similarity Score3%

Mitchell S Cairo, MD

New York Medical College

Related
13 trials

Shared therapeutic areas:

Classical Hodgkin LymphomaHodgkin Disease
Similarity Score3%

John D. Hainsworth, MD

SCRI Development Innovations, LLC

Related
26 trials

Shared therapeutic areas:

Lymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Worked with same sponsors:

BayerGenentech, Inc.
Similarity Score3%

Elias Jabbour, MD

M.D. Anderson Cancer Center

Related
15 trials

Shared therapeutic areas:

High Grade B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
Similarity Score3%

Tanya Trippett, MD

Memorial Sloan Kettering Cancer Center

Related
13 trials

Shared therapeutic areas:

Hodgkin DiseaseLymphoma, Non-Hodgkin

Worked with same sponsors:

Genentech, Inc.
Similarity Score3%

Publications (0)

No publications found for this investigator.

Clinical Trials (5)

Showing 5 of 5 trials

NCT04231877Phase 1/2PrincipalInvestigator

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Aggressive Non-Hodgkin LymphomaALK-Positive Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise Specified+6 more
Active Not Recruiting
NCT04156828Phase 1PrincipalInvestigator

Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

Grade 3b Follicular LymphomaNon-Hodgkin's LymphomaRecurrent Diffuse Large B-Cell Lymphoma+2 more
Terminated
NCT04155840Phase 2PrincipalInvestigator

Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic LeukemiaLymphoid LeukemiaNon-Hodgkin's Lymphoma+1 more
Terminated
NCT03776864Phase 2PrincipalInvestigator

Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Hodgkin's Lymphoma
Terminated
NCT03331341Phase 1/2PrincipalInvestigator

Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma

Classical Hodgkin Lymphoma
Completed

All 5 trials loaded